Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Terminated 1No longer available 1Completed 1

Sponsor Class

INDUSTRY 3

Study Type

Interventional 2Expanded_access 1

Sponsor

Cancer Type

Plasma cell 3Lymphoid 3CNS 2Thoracic 1Sarcoma 1Other hematologic neoplasm 1

Conditions

Lymphoma, Large-Cell, Anaplastic 3Granuloma, Plasma Cell 3Rhabdomyosarcoma 1Neuroblastoma 1Neoplasms 1Hematologic Neoplasms 1Glioblastoma 1Carcinoma, Non-Small-Cell Lung 1

Interventions

Crizotinib 4ceritinib 3pazopanib 2Ifosfamide 2Doxorubicin 2selinexor 1repotrectinib 1brigatinib 1Suspensions 1Radiotherapy 1Radiation 1Proton Therapy 1Capsules 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Granuloma, Plasma Cell × ceritinib × Plasma cell × Clear all
NCT05100134 2026-04-01

Managed Access Programs for LDK378, Ceritinib

Novartis

No longer available
LymphoidPlasma cellThoracic

Carcinoma, Non-Small-Cell Lung, Granuloma, Plasma Cell, Lymphoma, Large-Cell, Anaplastic

NCT01742286 2020-06-09

Phase I Study of LDK378 in Pediatric, Malignancies With a Genetic Alteration in Anaplastic Lymphoma Kinase (ALK)

Novartis

Phase 1 Completed
83 enrolled 30 charts
CNSLymphoidPlasma cellSarcoma

Granuloma, Plasma Cell, Neoplasms, Neuroblastoma, Rhabdomyosarcoma, Lymphoma, Large-Cell, Anaplastic

NCT02465528 2019-12-27

Ceritinib Rare Indications Study in ALK+ Tumors

Novartis

Phase 2 Terminated
22 enrolled 16 charts
CNSLymphoidOther hematologic neoplasmPlasma cell

Glioblastoma, Granuloma, Plasma Cell, Lymphoma, Large-Cell, Anaplastic, Hematologic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡